Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study
- PMID: 11142574
- DOI: 10.1016/s1590-8658(00)80327-8
Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study
Abstract
Background: Antibiotic-resistant Helicobacter pylori strains are becoming increasingly prevalent, although it is not clear to what extent the new resistant organisms will spread.
Aim: To evaluate the incidence of secondary Helicobacter pylori resistance to metronidazole, clarithromycin and/or amoxycillin after one-week proton pump inhibitor based triple therapy failure in patients who were, before therapy infected with Helicobacter pylori strains susceptible to these antibiotics.
Patients and methods: Enrolled in the study were 97 consecutive Helicobacter pylori-positive subjects infected by Helicobacter pylori strains susceptible to metronidazole, clarithromycin and amoxycillin. Activity of tested antibiotics was determined by means of the E-test. Patients were treated for seven days with a proton pump inhibitor, omeprazole 20 mg twice daily or pantoprazole 40 mg once daily, plus clarithromycin 250 mg twice daily and metronidazole 250 mg four times daily; or with a proton pump inhibitor plus amoxycillin 1 g twice daily and clarithromycin 500 mg twice daily. Two months after completion of therapy, endoscopy and gastric biopsies for histology, rapid urease test and culture were repeated.
Results: Four patients were dropped from the study Overall Helicobacter pylori cure rates expressed as both intention-to-treat and per-protocol analyses, were, respectively 80% (40/50) and 81.6% (40/49) with proton pump inhibitor, clarithromycin and metronidazole and 76.6% (36/47) and 81.8% (36/44) with proton pump inhibitor amoxycillin and clarithromycin. No significant differences were observed between the two treatments. Subjects in whom treatment failed were significantly younger and had less active ulcer than cured patients. Of treatment failures, 70.6% (12 out of 17 subjects) de veloped a secondary resistance to metronidazole (35.33% and/or clarithromycin (64.7%). Secondary antibiotic resistance occurred in 77. 8% of treatment failures treated with proton pump inhibitor, clarithromycin and metronidazole and in 62.5% of those treated with proton pump inhibitor, amoxycillin and clarithromycin. Considering all patients treated, the overall incidence of secondary metronidazole and/or clarithromycin resistance after therapy was reported in 12.9% of subjects (12 out of 93 treated patients).
Conclusions: Secondary Helicobacter pylori resistances to metronidazole and/or clarithromycin occurred in large percentages in patients with treatment failure after the one-week proton pump inhibitor-based triple therapies, proton pump inhibitor, clarithromycin and metronidazole and proton pump inhibitor, amoxycillin and clarithromycin. It is likely that new antibiotics or treatment strategies will be needed in the near future to successfully treat Helicobacter pylori infection.
Comment in
-
Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy.Dig Liver Dis. 2000 Nov;32(8):673-5. doi: 10.1016/s1590-8658(00)80328-x. Dig Liver Dis. 2000. PMID: 11142575 No abstract available.
Similar articles
-
Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment.J Antimicrob Chemother. 2016 Oct;71(10):2740-53. doi: 10.1093/jac/dkw220. Epub 2016 Jun 23. J Antimicrob Chemother. 2016. PMID: 27342548 Review.
-
Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication.Scand J Gastroenterol. 1999 Aug;34(8):750-6. doi: 10.1080/003655299750025660. Scand J Gastroenterol. 1999. PMID: 10499474 Clinical Trial.
-
Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.Aliment Pharmacol Ther. 1999 Apr;13(4):489-96. doi: 10.1046/j.1365-2036.1999.00504.x. Aliment Pharmacol Ther. 1999. PMID: 10215733 Clinical Trial.
-
Clinical relevance of resistant strains of Helicobacter pylori: a review of current data.Gut. 1998 Jul;43 Suppl 1(Suppl 1):S61-5. doi: 10.1136/gut.43.2008.s61. Gut. 1998. PMID: 9764043 Free PMC article. Review.
-
A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori.Aliment Pharmacol Ther. 1997 Oct;11(5):913-7. doi: 10.1046/j.1365-2036.1997.00230.x. Aliment Pharmacol Ther. 1997. PMID: 9354200 Clinical Trial.
Cited by
-
Identification of Antimotilins, Novel Inhibitors of Helicobacter pylori Flagellar Motility That Inhibit Stomach Colonization in a Mouse Model.mBio. 2022 Apr 26;13(2):e0375521. doi: 10.1128/mbio.03755-21. Epub 2022 Mar 1. mBio. 2022. PMID: 35227071 Free PMC article.
-
Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.Expert Rev Anti Infect Ther. 2018 Sep;16(9):679-687. doi: 10.1080/14787210.2018.1511427. Epub 2018 Aug 23. Expert Rev Anti Infect Ther. 2018. PMID: 30102559 Free PMC article. Review.
-
In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pylori.Antimicrob Agents Chemother. 2014 Jun;58(6):3255-60. doi: 10.1128/AAC.02573-13. Epub 2014 Mar 31. Antimicrob Agents Chemother. 2014. PMID: 24687512 Free PMC article.
-
Rescue Therapy for Helicobacter pylori Infection 2012.Gastroenterol Res Pract. 2012;2012:974594. doi: 10.1155/2012/974594. Epub 2012 Feb 28. Gastroenterol Res Pract. 2012. PMID: 22536225 Free PMC article.
-
Second-line rescue therapy of helicobacter pylori infection.Therap Adv Gastroenterol. 2009 Nov;2(6):331-56. doi: 10.1177/1756283X09347109. Therap Adv Gastroenterol. 2009. PMID: 21180581 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical